Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 4, 2007, Pages 463-469

  Al Mohri, Huda ^a   Murphy, Tanya ^b   Lu, Ying ^b   Lalonde, Richard G ^b   Klein, Marina B ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Alanine aspartyl transferase to platelet ratio index; Hepatic fibrosis; Hepatitis C virus; Highly active antiretroviral therapy; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; STAVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BACTERIAL PERITONITIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME BLOOD LEVEL; ESOPHAGUS VARICES; EVALUATION; FEMALE; HAZARD RATIO; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 34147108728     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318030ff8e     Document Type: Article

References (33)

1. Martin P, Di Bisceglie AM, Kassianides C, et al. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology. 1989;97:1559-1561.
2. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003;36:491-498.
3. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
4. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis. 2001;183:134-137.
5. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol. 1996;91:2563-2568.
6. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
7. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805.
8. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29:378-387.
9. Tatsunami S, Taki M, Shirahata A, et al. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol. 2004;111:181-184.
10. Fuster D, Planas R, Muga R, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:1293-1297.
11. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163-2170.
12. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128-133.
13. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology. 2005;41:123-131.
14. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283-287.
15. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713.
16. Sabin CA, Walker AS, Dunn D. HIV/HCV coinfection, HAART, and liver-related mortality. Lancet. 2004;364:757-758 [author reply: 758].
17. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
18. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767-774.
19. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376-1382.
20. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
21. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40:538-544.
22. Al-Mohri H, Cooper C, Murphy T, et al. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C (HCV) co-infected patients. Presented at: 14th Annual Canadian Conference on HIV/AIDS Research; 2005; Vancouver.
23. Murphy DG, Cote L, Fauvel M, et al. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2000;38:4034-4041.
24. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS. 1998;12:116-117.
25. Zylberberg H, Pialoux G, Carnot F, et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis. 1998;27:1255-1258.
26. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
27. Martin-Carbonero L, Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS. 2005;19:621-623.
28. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597.
29. Klein M, Al-Mohri H, Murphy T, et al. Contribution of drug use and lifestyle to hepatic fibrosis in HIV-HCV co-infection. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
30. Petry NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS. 1999;10:561-570.
31. Sterling R, Lissen E, Clumeck N, et al. Can routine non-invasive tests predict liver histology in HIV/HCV co-infection? Analysis of patients entering the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT) [abstract 120]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
32. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
33. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-992.